List view / Grid view

Dr Raffaele Colombo (Zymeworks)



Unlocking the potential of antibody drug conjugates

1 May 2024 | By , ,

Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…